Aerobic training reduces blood pressure and waist circumference and increases HDL-c in metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials

Abstract Background and aims: Intermittent fasting (IF) has gained attention as a promising diet for weight loss and dysmetabolic diseases management. This systematic review aimed to investigate the effects of IF on metabolic syndrome (MetS). Methods: A systematic literature search was carried out using three electronic databases, namely PubMed, Embase, and the Cochrane Library, until October 2020. Randomized controlled trials that compared the IF intervention with a control group diet were included. Effect sizes were expressed as weighted mean difference (WMD) using a fixed-effects model and 95% confidence intervals (CI). Results: Forty-six studies were included. Compared to the ones within control groups, participants exposed to the IF intervention reduced their body weight (WMD, -1.78 kg; 95% CI, -2.21 to -1.35; p < 0.05), waist circumference (WMD, -1.19 cm; 95% CI, -1.8 to -0.57; p < 0.05), fat mass (WMD, -1.26 kg; 95% CI, -1.57 to -0.95; p < 0.05), body mass index (WMD, -0.58 kg/m2; 95% CI, -0.8 to -0.37; p < 0.05), systolic blood pressure (WMD, -2.14 mmHg; 95% CI: -3.54 to -0.73; p < 0.05), diastolic blood pressure (WMD: -1.38 mmHg, 95% CI, -2.35 to -0.41, p < 0.05), fasting blood glucose (WMD, -0.96 mg/dL; 95% CI, -1.89 to -0.03; p < 0.05), fasting insulin (WMD, -0.8 μU/mL; 95% CI, -1.15 to -0.44; p < 0.05), insulin resistance (WMD, -0.21; 95% CI, -0.36 to -0.05; p < 0.05), total cholesterol (WMD, -3.75 mg/dL; 95% CI, -6.64 to -0.85; p < 0.05), triglycerides (WMD, -7.54 mg/dL; 95% CI, -11.45 to -3.63; p < 0.05). No effects were observed for low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or glycosylated hemoglobin. Conclusions: This meta-analysis supports IF’s role in the improvement of MetS, compared to a control group diet. Further research on IF interventions should take into account long-term and well-designed administration to draw definitive conclusions.

Download Full-text

The Effects of Quercetin Supplementation on Blood Pressures and Endothelial Function Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Current Pharmaceutical Design ◽

10.2174/1381612825666190513095352 ◽

2019 ◽

Vol 25 (12) ◽

pp. 1372-1384 ◽

Cited By ~ 4

Author(s):

Omid R. Tamtaji ◽

Alireza Milajerdi ◽

Ehsan Dadgostar ◽

Fariba Kolahdooz ◽

Maryam Chamani ◽

...

Keyword(s):

Systematic Review ◽

Blood Pressure ◽

Metabolic Syndrome ◽

Endothelial Function ◽

Randomized Controlled Trials ◽

Adhesion Molecule ◽

Meta Analysis ◽

Controlled Trials ◽

Randomized Controlled ◽

Blood Pressures

Background: This systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to determine the effect of quercetin administration on blood pressures and endothelial function among patients with metabolic syndrome (MetS) and related disorders. Methods: We searched systematically online databases including Cochrane Library, EMBASE, MEDLINE, and Web of Science to identify the relevant RCTs until December 2018. Q-test and I2 statistics were applied to assess heterogeneity among the included studies. Data were pooled using a random-effects model and weighted mean difference (WMD) was considered as the overall effect size. Results: Out of 284 citations, 8 RCTs were included in the meta-analysis. We found a significant reduction in systolic blood pressure (SBP) (WMD: -1.69; 95% CI: -3.22, -0.17) following the intake of quercetin supplements. However, quercetin supplementation did not significantly affect diastolic blood pressure (DBP) (WMD: -3.14; 95% CI: -8.24, 1.95), vascular cell adhesion molecule 1 (VCAM-1) (WMD: -24.49; 95% CI: -53.74, 4.77) and intercellular adhesion molecule 1 (ICAM-1) (WMD: -5.78; 95% CI: -12.93, 1.38). Conclusions: In summary, the current meta-analysis demonstrated that quercetin supplementation significantly reduced SBP, yet did not affect DBP, VCAM-1 and ICAM-1 among patients with MetS and related disorders.

Download Full-text